Innovator’s Pitch Challenge

Vote for Us

Interested in Connecting? Please contact:
Luke Neill
VP, Clinical Affairs
luke@cardiosense.com

Message the company or request a 1:1 meeting here

Detecting the early signs of cardiac decline has traditionally required invasive devices only available in intensive care settings. Despite evidence the same insights can be captured noninvasively using AI, data quantity, quality, and access remain barriers to adoption. Cardiosense is building a novel hardware and software platform specifically designed to capture high-fidelity physiological waveforms and develop digital biomarkers to unobtrusively assess cardiac function.